CClinicalTrials.gg
Sign In
Status unknownNCT00465283Updated Jan 27, 2009

Donepezil Double Blind Trial for ECT Memory Disfunction

A Phase 4 interventional study of Donepezil in Schizophrenia, Schizoaffective Disorder and Schizophreniform Disorder, sponsored by BeerYaakov Mental Health Center. Status unknown at 1 site in Israel. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2009-01-27.

Sponsored by BeerYaakov Mental Health Center · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2009), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a double blind randomized investigation of donepezil for patients suffering from schizophrenia, undergoing ECT.

Patients will be randomized to receive either donezepil or plasebo, in order to gauge whether donezepil has a protective effect on memory disfunction, while patients are treated with ECT. Several parameters will be invistigated at baseline: general psychopathological measures, memory function scales, side effects scales. The same measurements will be taken throughout the trial and one month after ending the ECT.

02

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder
  • Schizophreniform Disorder

Keywords

  • Donepezil, ECT, Memory Disfunction
03

In context

Schizophrenia

3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.

This study's planned enrollment of 40 is below the median of 70 across 2,872 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

BeerYaakov Mental Health Center is the lead sponsor of 17 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Schizophrenia, Schizoaffective disorder, schizophreniform disorder patients who meet criteria for diagnoses by DSM-IV criteria and evaluated by the Structured Clinical Interview for DSM-IV (SCID)

Exclusion criteria

Exclusion Criteria:

  • History of serious neurological disorders including neurodegenerative deseases, mental retardation, substance and/or alcohol dependence.
  • Pregnant women
  • Patients who recieved ECT within 6 month
  • Patients whith contraindication to Donepezil treatment.
  • Patients with Lithium treatment
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Donepezil

    Drug: Donepezil

  • Placebo comparator
    placebo

    Drug: Donepezil

Interventions

  • DrugDonepezil

    Tab.Donepezil 5 mg once daily during ECT treatment and the month after the last ECT treatment

    Also known as: Donepezil - Memorit

06

What researchers measure

Primary outcomes

  1. Data will be analyzed using SPSS for Windows.

    Time frame: after 5 ECT treatments

  2. Results of the memory and neurocognitive measures will be examined

    Time frame: after 8 ECT treatments

  3. using repeated MANOVA with before, within and after ECT treatment.

    Time frame: 1 month after the last ECT treatment

07

Study locations

1 of 1 sites recruiting
  • Beer Yaakov MHC
    Beer Yaacov, 70350, Israel
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 27, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00465283
Lead sponsor
BeerYaakov Mental Health Center
First posted
Apr 24, 2007
Start date
May 2007
Primary completion
Jan 2010 (estimated)
Completion
Jan 2010 (estimated)
Last update
Jan 27, 2009

Study contacts

Tali Nachshoni, MD
Contact
bynachshoni@beer-ness.health.gov.il
972-8-9258372
Marina Kupchik, MD
Contact
kupchik@beer-ness.health.gov.il
972-89258382
Tali Nachshoni, MD
principal investigator · Beer Yaakov Mental Health Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Schizophrenia→

Other studies from this sponsor

BeerYaakov Mental Health Center

Start the discussion